Journal Article

<i>Campylobacter jejuni</i> Strain CG8421: A Refined Model for the Study of Campylobacteriosis and Evaluation of <i>Campylobacter</i> Vaccines in Human Subjects

David R. Tribble, Shahida Baqar, Marya P. Carmolli, Chad Porter, Kristen K. Pierce, Katrin Sadigh, Patricia Guerry, Catherine J. Larsson, David Rockabrand, Cassandra H. Ventone, Frederic Poly, Caroline E. Lyon, Sandra Dakdouk, Ann Fingar, Theron Gilliland, Patrick Daunais, Erika Jones, Stacia Rymarchyk, Christopher Huston, Michael Darsley and Beth D. Kirkpatrick

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 49, issue 10, pages 1512-1519
Published in print November 2009 | ISSN: 1058-4838
Published online November 2009 | e-ISSN: 1537-6591 | DOI:
Campylobacter jejuni Strain CG8421: A Refined Model for the Study of Campylobacteriosis and Evaluation of Campylobacter Vaccines in Human Subjects

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Background. A robust human challenge model for Campylobacter jejuni is an important tool for the evaluation of candidate vaccines. The previously established model conveys a potential risk of Guillain-Barré syndrome attributable to lipooligosaccharide ganglioside mimicry. This work establishes a new C. jejuni human challenge model that uses a strain (CG8421) without ganglioside mimicry and that applies Campylobacter -specific cellular immunity screening to achieve high attack rates at lower inoculum doses.

Methods. Healthy Campylobacter -naive adults participated in an open-label challenge trial. Participants were dosed with C. jejuni CG8421 and followed as inpatients. Pattern of illness, bacterial shedding, and immunologic responses were determined.

Results. Following screening, 23 subjects received 1×106or 1×105colony-forming units of C. jejuni, with attack rates (percentage of patients who became ill) of 100% (1×106colony-forming units) or 93% (1×105colony-forming units). Every subject shed CG8421; the median time to diarrhea onset was 72.3 h (interquartile range, 53.9–99.9 h). Symptoms included abdominal cramps (74%), nausea (65%), and fever (39%). No major safety concerns occurred, including bacteremia, hypotension, or postinfectious sequelae. Unexpectedly, recrudescent infection occurred in 2 subjects (1 subject without Campylobacter -specific adaptive immune responses and 1 with azithromycin resistance acquired in vivo); both infections cleared after receipt of additional antibiotics. Cumulative Campylobacter -specific immune responses were as follows: serologic response occurred in 87% (immunoglobulin [Ig] A) and 48% (IgG) of subjects, in vitro interferon-γ production occurred in 91% of subjects, and 96% of subjects had IgA antibody-secreting cells and fecal IgA detected.

Conclusions. The C. jejuni CG8421 challenge model provides a safe and effective tool, without the risk of Guillain-Barré syndrome. The model demonstrates high attack rates after lower doses of challenge inoculum, provides further understanding of immunologic responses, and permits future investigation of candidate Campylobacter vaccines.

Journal Article.  4224 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.